- Home
- KBR vs LEGN Comparison
KBR vs LEGN Comparison
Compare KBR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | LEGN |
|---|---|---|
| Founded | 1901 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KBR | LEGN |
|---|---|---|
| Price | $42.48 | $22.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $55.00 | ★ $69.58 |
| AVG Volume (30 Days) | 1.5M | ★ 2.5M |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 21.27 | N/A |
| EPS | ★ 2.89 | N/A |
| Revenue | ★ $8,041,000,000.00 | $909,045,000.00 |
| Revenue This Year | $2.39 | $68.52 |
| Revenue Next Year | $4.10 | $48.63 |
| P/E Ratio | $14.86 | ★ N/A |
| Revenue Growth | 9.67 | ★ 74.75 |
| 52 Week Low | $39.52 | $20.21 |
| 52 Week High | $60.98 | $45.30 |
Technical Indicators
Market Signals| Indicator | KBR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.34 | 41.51 |
| Support Level | $40.01 | $20.21 |
| Resistance Level | $43.47 | $22.07 |
| Average True Range (ATR) | 1.00 | 0.80 |
| MACD | 0.21 | 0.21 |
| Stochastic Oscillator | 70.91 | 65.68 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.